Please assess the completion status of the following clinical trial:

Trial Title: Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV infection~Exclusion Criteria:~* cancer severe jaundice pulmonary and renal chronic diseases prostatic diseases autoimmune diseases diabetes mellitus decompensated cirrhosis pregnancy hemoglobinopathies hemocromatosis

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Silybin - vitamin E - phospholipids complex (Type: ACTIVE_COMPARATOR): Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill for 12 months.
- placebo (Type: PLACEBO_COMPARATOR): sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).